Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
1.650
+0.100 (6.45%)
Feb 18, 2026, 4:00 PM EST - Market closed
Invivyd Employees
As of December 31, 2024, Invivyd had 100 total employees, including 99 full-time and 1 part-time employees. The number of employees increased by 5 or 5.26% compared to the previous year.
Employees
100
Change (1Y)
5
Growth (1Y)
5.26%
Revenue / Employee
$500,390
Profits / Employee
-$598,620
Market Cap
465.28M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 100 | 5 | 5.26% | 99 | 1 |
| Dec 31, 2023 | 95 | 9 | 10.47% | 94 | 1 |
| Dec 31, 2022 | 86 | -17 | -16.50% | 84 | 2 |
| Dec 31, 2021 | 103 | - | - | 101 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Kyverna Therapeutics | 129 |
| Solid Biosciences | 100 |
| Verastem | 78 |
| Assembly Biosciences | 73 |
| Lexeo Therapeutics | 61 |
| PepGen | 57 |
| PureTech Health | 56 |
| Zura Bio | 30 |
IVVD News
- 15 days ago - Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration - GlobeNewsWire
- 4 weeks ago - Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 - GlobeNewsWire
- 5 weeks ago - Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - GlobeNewsWire
- 2 months ago - Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - GlobeNewsWire
- 3 months ago - Invivyd to Participate at the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 3 months ago - Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness - GlobeNewsWire
- 3 months ago - Invivyd: Maintaining Hold Rating With VYD2311 Alternative To Covid-19 Vaccination - Seeking Alpha